Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019

May 23, 2019 — Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron...

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b...

Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019

May 13, 2019 — Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F))...

Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor

May 10, 2019 — Shine Medical Technologies Inc. broke ground on their first...

Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019

March 14, 2019 — A team of researchers at the University of Washington announced they developed a new automated...

ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019

January 30, 2019 - ImaginAb Inc. announced the enrollment of the first patient in the Phase II...

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019

January 16, 2019 — MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018

November 13, 2018 — The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-...

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018

November 7, 2018 — With the recent announcement by Novartis to acquire Endocyte , interest from the conventional...

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the...

PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018

September 5, 2018 — Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of...

Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018

August 24, 2018 — In a small study...

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018

June 13, 2018 — A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine...

PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018

May 17, 2018 — A novel positron emission...

News | Radiopharmaceuticals and Tracers | May 09, 2018

May 9, 2018 — Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a...

News | Radiopharmaceuticals and Tracers | May 03, 2018

May 3, 2018 — BWX Technologies Inc. signed a definitive agreement to acquire Sotera Health’s Nordion...

Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018

April 10, 2018 — Researchers have developed a new imaging agent that could help guide and assess treatments for...

The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell

April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear...

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018

February 21, 2018 — Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the...

A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell

February 8, 2018 — The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently...